Show Notes
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms!
"Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods."
Meet the guest: Dr. Jason Itri https://www.linkedin.com/in/jason-itri-20962326/ is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care.
What you will learn: (00:00) Highlight (00:48) Introduction (04:49) Microdosing strategy (07:07) Habit control (14:51) Risk markers (16:51) Insulin resistance (28:50) Muscle loss (32:00) Final Questions
๐๐ถ๐๐๐ฒ๐ป ๐ผ๐ป ๐๐ฝ๐ฝ๐น๐ฒ ๐ฃ๐ผ๐ฑ๐ฐ๐ฎ๐๐๐, ๐ฆ๐ฝ๐ผ๐๐ถ๐ณ๐ ๐ผ๐ฟ ๐ฎ๐ป๐ ๐บ๐ฎ๐ท๐ผ๐ฟ ๐ฝ๐น๐ฎ๐๐ณ๐ผ๐ฟ๐บ. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
More from The GLP-1 Podcast Show
In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michelle Gordon, a physician board-certified in obesity medicine and CEO of Thrive Span Medical, about obesity care for women in midlife. We discuss how GLP-1 therapy fits into long-term disease management, why slower weight reduction, adequate protein, resistance training, hydration, and fiber matter, and how hormonal changes may affect weight, cognition, and metabolic health. Dr. Gordon also explains when bariatric surgery remains appropriate and why obesity should be treated as a complex chronic disease. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ashley Koff, registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot, about weight health in the GLP-1 era. She explains why body composition matters more than total weight, how digestion and hydration shape nutrition outcomes, why protein advice must be personalized, and how clinicians can support more sustainable metabolic health. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms.